GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

TK006

Company
Jiangsu T-Mab Biopharma Co.,Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT02470091

    Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

    Not yet reported Children's Oncology Group 56 participants Est. completion 2023-12-31 141 sites
    Obstructive sleep apnea
    View official trial listing →
  • Status unknown NCT NCT03239756

    Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases

    Not yet reported Jiangsu T-Mab Biopharma Co.,Ltd 40 participants Est. completion 2018-08 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03242512

    Assessment of Anti-RANKL Antibody in Post-menopausal Women

    Not yet reported Jiangsu T-Mab Biopharma Co.,Ltd 24 participants Est. completion 2018-12-30 1 site Stand-alone
    Other conditions: Osteoporosis
    View official trial listing →
  • Terminated NCT NCT03382574

    Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

    Not yet reported National Cancer Institute (NCI) 2 participants Est. completion 2021-10-22 6 sites
    Other conditions: Ovarian Carcinoma
    View official trial listing →
  • Status unknown NCT NCT03487055

    Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

    Not yet reported Jiangsu T-Mab Biopharma Co.,Ltd 30 participants Est. completion 2019-05 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.